NCT02064374 - Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

Metformin 500 mg q12h

Metformin will be supplied as 500 mg tablet to be administered orally.

DRUG

Dolutegravir 50 mg q24h

Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)

DRUG

Dolutegravir 50 mg q12h

Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).

Trial Locations (1)

66211

GSK Investigational Site, Overland Park